Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Cold-exposed mothers pass metabolic protection to male rat offspring through milk

Maternal cold exposure during early pregnancy improved glucose control and reduced liver fat in male rat offspring, with benefits persisting into late adulthood. The findings implicate a breast milk LCA, gut microbiota, and Th17 immune pathway, while human cohort data showed an observational link between winter conception and lower MASLD risk.

12 Jul 2026

Novel strategy can make stem cell transplants safer

Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, b-thalassemia, immune deficiencies, and some blood cancers.

8 Jul 2026

Strategic collaboration funds interdisciplinary projects to improve cancer care

Rice University's Synthesis X Center and Houston Methodist Neal Cancer Center have awarded $90,000 in seed grants as part of a new strategic collaboration.

8 Jul 2026

Study reveals why patients with rare leukemia develop resistance to tagraxofusp

Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-approved treatment for this disease.

7 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

New genome editing tool unlocks fungi's hidden drug-producing potential

Researchers have spent decades-and billions of dollars-sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining bread or colonizing toes.

2 Jul 2026

Simple donor message could expand stem cell transplant options

When a patient needs a stem cell transplant, finding a registered donor is only the first step. Some potential donors drop out before confirmatory typing, reducing the pool from which doctors can choose.

2 Jul 2026

Study explains how leukemia creates inflammatory lung environments

Acute myeloid leukemia (AML) does more than infiltrate the lungs: it also transforms lung tissue to create an inflammatory environment that promotes the expansion of tumor cells and impairs respiratory function.

30 Jun 2026

Study reveals how leukemia cells invade lungs and cause breathing problems

Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

29 Jun 2026

Unusual CD34+ dysplastic giant platelets complicate myelodysplastic syndrome diagnosis

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by ineffective hematopoiesis, with manifestations of cytopenias in one, two, or three lineages.

28 Jun 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

AI-driven approach identifies promising new target for CAR T cell therapy

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.

25 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Novel technology maps single-cell DNA-protein interactions

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

4 Jun 2026

New all-oral regimen improves treatment convenience for AML patients

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

3 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

21 May 2026

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor when tumors spread to the lungs or return after treatment.

20 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026